Novel systemic therapies in advanced liposarcoma: A review of recent clinical trial results

William W. Tseng; Neeta Somaiah; Alexander J. Lazar; Dina C. Lev; Raphael E. Pollock

doi:10.3390/cancers5020529

Novel systemic therapies in advanced liposarcoma: A review of recent clinical trial results

William W. Tseng, Neeta Somaiah, Alexander J. Lazar, Dina C. Lev, Raphael E. Pollock

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.

Original language	English (US)
Pages (from-to)	529-549
Number of pages	21
Journal	Cancers
Volume	5
Issue number	2
DOIs	https://doi.org/10.3390/cancers5020529
State	Published - Jun 2013

Keywords

Chemotherapy
Clinical trials
Liposarcoma
Molecular-based therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers5020529

Cite this

@article{a13cc5061ef1493c84a23ae9030cebcc,

title = "Novel systemic therapies in advanced liposarcoma: A review of recent clinical trial results",

abstract = "Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.",

keywords = "Chemotherapy, Clinical trials, Liposarcoma, Molecular-based therapy",

author = "Tseng, {William W.} and Neeta Somaiah and Lazar, {Alexander J.} and Lev, {Dina C.} and Pollock, {Raphael E.}",

year = "2013",

month = jun,

doi = "10.3390/cancers5020529",

language = "English (US)",

volume = "5",

pages = "529--549",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Novel systemic therapies in advanced liposarcoma

T2 - A review of recent clinical trial results

AU - Tseng, William W.

AU - Somaiah, Neeta

AU - Lazar, Alexander J.

AU - Lev, Dina C.

AU - Pollock, Raphael E.

PY - 2013/6

Y1 - 2013/6

N2 - Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.

AB - Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.

KW - Chemotherapy

KW - Clinical trials

KW - Liposarcoma

KW - Molecular-based therapy

UR - http://www.scopus.com/inward/record.url?scp=84878840310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878840310&partnerID=8YFLogxK

U2 - 10.3390/cancers5020529

DO - 10.3390/cancers5020529

M3 - Review article

C2 - 24216990

AN - SCOPUS:84878840310

SN - 2072-6694

VL - 5

SP - 529

EP - 549

JO - Cancers

JF - Cancers

IS - 2

ER -

Novel systemic therapies in advanced liposarcoma: A review of recent clinical trial results

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this